PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Am J Addict. Author manuscript; available in PMC 2017 April 1.
Published in final edited form as:
PMCID: PMC4818002
NIHMSID: NIHMS769739

Baseline Medical Comorbidities in Adults Randomized in the STRIDE Trial for Psychostimulant Use Disorders

Abstract

Background and Objectives

Rates of medical illnesses may be higher among individuals with substance use disorders, complicating their care. This study aimed to expand the understanding of other medical conditions in treatment-seeking adults with stimulant use disorder (SUD) using data from Stimulant Reduction Intervention using Dose Exercise (STRIDE), a randomized, multisite trial investigating exercise augmentation of treatment as usual.

Methods

Utilizing STRIDE baseline data, we examined demographic and clinical characteristics based on the number of self-reported diagnosed medical conditions among participants meeting eligibility criteria (passing medical screening exam and maximal exercise test, non-opioid dependent, no concomitant beta blocker or opioid replacement therapy).

Results

The majority (59%) of study participants (N=302, mean age all participants = 39 years) did not report any history of other medical problems. Those with two or more conditions were older (mean age 46 years), reported more pain and worse physical functioning, and more psychiatric disorders (average 1.44). Hypertension was more common among participants with cocaine use disorders only (present in 16%) and liver disease was more common in those with cocaine plus other stimulant use disorders (present in 7%).

Conclusion and Scientific Significance

In this sample, patients with SUD were in surprisingly good health. A subpopulation had an overall higher burden of illness with worsened physical and psychiatric functioning. Provision of coordinated care may optimize treatment outcomes for patients based on medical comorbidity burden as well as type of drug abused, although these conclusions should be considered preliminary as they are based on self-reported data.

Introduction

Adults with stimulant (cocaine, amphetamine, methamphetamine) use disorders (SUD) are reported to have higher rates of other medical conditions 1, 2. Several aspects of the nature of additional medical conditions among patients with SUD remain uninvestigated. Little has been reported on the health status of users of stimulants other than cocaine. Only two reports have examined differences among stimulants, both demonstrating differences among methamphetamine users compared to cocaine users 3, 4. This previous work is limited by focus on one geographical area (rural areas of Ohio, Kentucky, and Arkansas) 3-8 and use of non-standard criteria for determining SUD.

The current study aimed to expand understanding of other medical conditions in treatment-seeking adults with SUD following a maximal cardiac stress test through a secondary analysis of baseline data from the Stimulant Reduction Intervention using Dose Exercise (STRIDE) trial. The first aim examined the relationship between demographic and clinical characteristics with the number of self-reported medical conditions. We then compared the rates of common medical conditions between three different groups of participants: cocaine use disorder only; other stimulant use disorder only; and concurrent cocaine and other stimulant use disorder.

Methods

The multisite STRIDE trial (CTN-0037), conducted within the National Institute on Drug Abuse Clinical Trials Network, tested the efficacy of aerobic exercise compared to health education as augmentation to treatment as usual for SUD 9. Information pertinent to the current analysis is given below. Data for the present study were collected at baseline, after eligibility was confirmed but prior to randomization into treatment groups.

Participants

STRIDE participants (N=302) were adult men and women admitted to residential substance abuse treatment with use of a stimulant (primarily cocaine, methamphetamine, or amphetamine) in the 30 days prior to treatment entry and meeting DSM IV-TR diagnosis of stimulant abuse or dependence in the 12 months prior to treatment entry. Exclusion criteria included: inability to pass medical clearance or general medical condition that prevented exercise; opioid dependence; psychosis or psychiatric safety risk; pregnancy; or concomitant therapy with beta blockers or opioid replacement therapy. Thus, exclusion criteria ensured participants were healthy enough for moderate exercise yet were lenient enough to allow entry of participants with existing medical conditions. All protocols were approved by the Institutional Review Boards of the 9 participating sites and participants provided written informed consent.

Assessments

Measures reported in the current manuscript are described briefly below. The STRIDE trial collected additional outcome measures that were not included in this baseline report (e.g., drug use information [TimeLine FollowBack, urine drug screen], psychosocial, physiological, and cognitive measures) that are further described in the study design paper 9.

Demographic information was collected from all participants. DSM-IV-TR illicit drug use disorders were assessed with the World Health Organization Composite International Diagnostic Interview (CIDI) version 2.1 10.

Physical Health Measures

The Self-Administered Comorbidity Questionnaire (SCQ 11) was expanded for STRIDE to determine the presence of fifteen common medical problems. The SCQ is a self-administered health questionnaire that requires participants to answer yes or no for the presence of each condition and includes space for participants to write-in any other medical conditions. Participants indicate if they receive treatment for each condition and if activity is limited by each condition endorsed. The instrument is scored by summing the total number of conditions, treatments, and activity limitations. The Pain Frequency, Intensity, and Burden Scale (P-FIBS) 12 was used to determine pain symptoms in the week prior to study entry.

Mental Health Measures

Major DSM-IV-TR Axis I diagnoses other than drug use disorders were assessed with the MINI International Neuropsychiatric Interview (MINI) 13. Depressive symptoms were assessed with the Quick Inventory of Depressive Symptomatology-Clinician Rated version (16-item) 14. Anhedonia was assessed with the Snaith-Hamilton Pleasure Scale 15. Suicidal propensity and risk were assessed with the Concise Health Risk Tracking-Self Report (CHRT-SR) 16.

Functional Measures

Measures of functioning were the Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire 17, Quality of Life Enjoyment and Satisfaction Questionnaire Short Form 18, and Short-Form Health Survey (SF-36) 19.

Substance Use Measures

The Addiction Severity Index-Lite (ASI-Lite) assessed multiple aspects of substance use 20. The Stimulant Selective Severity Assessment assessed the signs and symptoms of stimulant abstinence 21. The Stimulant Craving Questionnaire-Brief assessed craving 22.

Data Analysis

Analysis of variance and χ2 tests were used to compare group means and frequencies for continuous and categorical variables, respectively. Demographic and clinical variables were compared among those reporting no comorbid medical conditions on the SCQ, those reporting one comorbid medical condition, and those reporting two or more comorbid medical conditions. No corrections for multiple comparisons were made. Differences were considered significant if p<0.05, although trends (0.05≤p<0.09) are also discussed. The rates of each of the conditions assessed by the SCQ were then compared between the following groups: cocaine use disorder only; other stimulant use disorder; and concurrent cocaine and other stimulant use disorder.

Results

Data for 299 participants are presented, as 3 participants had incomplete SCQ data. One hundred seventy-five participants (59%) reported no comorbid medical conditions on the SCQ, sixty-seven (22%) reported one comorbid condition, and fifty-seven (19%) reported two or more comorbid conditions. Table 1 presents sample demographic and clinical characteristics. In all cases of significant differences or trends, except where noted, those reporting 2 or more medical conditions were different from those reporting no medical conditions. Age and usual level of employment differed between groups; differences in employment were also significant on the ASI employment subscale. There were no differences between groups in race/ethnicity, current employment status, current employment income, or usual living arrangement (data not shown).

Table 1
Demographic and clinical characteristics of STRIDE participants based on number of reported medical conditions on the SCQ

Participants with more comorbid medical conditions reported worse pain (P-FIBS) and physical health (SF-36 physical component and ASI medical subscale). Participants with more medical conditions also demonstrated greater number of current psychiatric disorders (MINI and ASI psychiatric subscale) and trends towards greater depressive symptoms, anhedonia, and suicide propensity. No group differences were observed in suicide risk, overall perception of mental health (SF-36 mental component), or the lifetime number of major depressive episodes. A trend towards group differences was seen on the cognitive and physical functioning measure, with greater impairment in those with more conditions. There were no differences between groups in ratings of life satisfaction (Q-LES-Q) or impact of substance use/severity of addiction other than as discussed above.

Table 2 presents the relative frequency of each of the medical conditions queried on the SCQ based on stimulant use diagnosis. High blood pressure was more prevalent in those with cocaine use disorder only. Liver disease was more common in those with concurrent cocaine and other stimulant use disorders. All other conditions were evenly distributed across use disorder categories.

Table 2
Medical Conditions Reported on the SCQ by Substance Use Disorder

In order to evaluate individuals who were screened but not cleared to exercise, we assessed the reported rates of medical illnesses for 31 participants excluded from the study for medical reasons and for whom the SCQ was completed (note that 41 participants were excluded for medical reasons, but 10 were excluded prior to completion of the SCQ). High blood pressure (χ2=13.9, p<0.001) and diabetes (χ2=4.2, p<0.05) were more common among those who completed the SCQ and who were excluded from the study for medical reasons compared to the enrolled sample.

Discussion

Despite widely held beliefs that adults with SUD face a heavy burden of physical illness, the majority of STRIDE study participants reported no other medical conditions. Participants with two or more comorbid medical conditions, however, were distinct: older at study entry with worse overall health-related quality of life, higher pain levels, and greater psychiatric disease burden. Rates of comorbid medical illnesses were similar across different classes of stimulant users, with differences only in rates of hypertension and liver disease.

The overall low rate of reported comorbid medical illness may be related to our study population, given the well-documented association between SUD and physical illness 23-25. When interpreting our results, the limitations posed by the study sample and study design must be considered. The study sample excluded patients with a serious medical condition that prevented exercise, and therefore may be less representative of the general population of those with SUD. Furthermore, it is possible that those with more serious medical conditions were not interested in or informed of the study and thus did not complete the screening visit. It is also possible that participants had undiagnosed medical conditions that were therefore not self-reported; this suspicion is supported by the observation that the rates of some illness (e.g., hypertension) appear to be lower among the study population than among the general population. Of the 41 participants who were not medically cleared for study participation, we cannot characterize the exact medical reason for exclusion, which further limits the generalizability of our results. Additionally, the exclusion of opioid-dependent patients may account in part for the overall low rate of medical conditions, as opioid use has been associated with higher mortality 2, 26. Given the limited sample size of participants with medical conditions as well as alcohol/nicotine/marijuana use, we were not able to examine the potential impact of alcohol or smoking (either tobacco or marijuana) 27 on health status.

The strengths of our study are many: multisite design that allowed for inclusion of participants from many different regions of the United States, including urban and rural areas; thorough diagnosis of stimulant use and other psychiatric disorders; and comprehensive assessment of functioning. The inclusion of participants with any SUD allowed for comparison of rates of medical illness among groups of stimulant users. We identified a subset of patients with multiple medical conditions, who were older and also had a greater burden of psychiatric illness. This finding has treatment implications as those patients may require provision of coordinated care to optimize treatment outcomes. Importantly, we observed a subset of individuals with SUD who are in sufficiently good health and therefore may be in a position to adopt strategies, such as a physical activity, that maximize recovery.

Acknowledgments

Research reported in this publication was supported by the National Institute on Drug Abuse of the National Institutes of Health under Award Number U10DA020024 (PI: Trivedi) and NIMH award number K01MH097847 (PI: Rethorst). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Additional support from the Center for Depression Research and Clinical Care (CDRCC).

We thank Carol A. Tamminga, M.D., Lou and Ellen McGinley Distinguished Chair and the McKenzie Chair in Psychiatry and Chair, Department of Psychiatry, University of Texas Southwestern Medical Center. The authors also wish to thank Savitha Kalidas, PhD., for editorial assistance with manuscript preparation.

Footnotes

Potential Conflicts of Interest: Dr dela Cruz, Dr Carmody, Dr Rethorst, Dr Warden and Dr Walker have no disclosures to report.

The authors alone are responsible for the content and writing of this paper.

Dr. Greer has received research funding from NARSAD and honoraria and/or consultant fees from H. Lundbeck A/S and Takeda Pharmaceuticals International, Inc.

Dr. Trivedi, is or has been an advisor/consultant and received fee from (Lifetime disclosure): Abbott Laboratories, Inc., Abdi Ibrahim, Akzo (Organon Pharmaceuticals Inc.), Alkermes, AstraZeneca, Axon Advisors, Bristol-Myers Squibb Company, Cephalon, Inc., Cerecor, CME Institute of Physicians ,Concert Pharmaceuticals, Inc., Eli Lilly & Company, Evotec, Fabre Kramer Pharmaceuticals, Inc., Forest Pharmaceuticals, GlaxoSmithKline, Janssen Global Services, LLC, Janssen Pharmaceutica Products, LP, Johnson & Johnson PRD, Libby, Lundbeck, Meade Johnson, MedAvante, Medtronic, Merck, Mitsubishi Tanabe Pharma Development America, Inc., Naurex, Neuronetics, Otsuka Pharmaceuticals, Pamlab, Parke-Davis Pharmaceuticals, Inc., Pfizer Inc., PgxHealth, Phoenix Marketing Solutions, Rexahn Pharmaceuticals, Ridge Diagnostics, Roche Products Ltd., Sepracor, SHIRE Development, Sierra, SK Life and Science, Sunovion, Takeda, Tal Medical/Puretech Venture, Targacept, Transcept, VantagePoint, Vivus, and Wyeth-Ayerst Laboratories. In addition, he has received grants/research support from: Agency for Healthcare Research and Quality (AHRQ), Corcept Therapeutics, Inc., Cyberonics, Inc., Merck,National Alliance for Research in Schizophrenia and Depression, National Institute of Mental Health and National Institute on Drug Abuse.

References

1. Degenhardt L, Singleton J, Calabria B, et al. Mortality among cocaine users: a systematic review of cohort studies. Drug Alcohol Depend. 2011 Jan 15;113(2-3):88–95. [PubMed]
2. Merrall EL, Bird SM, Hutchinson SJ. Mortality of those who attended drug services in Scotland 1996-2006: record-linkage study. Int J Drug Policy. 2012 Jan;23(1):24–32. [PMC free article] [PubMed]
3. Garrity TF, Leukefeld CG, Carlson RG, Falck RS, Wang J, Booth BM. Physical health, illicit drug use, and demographic characteristics in rural stimulant users. J Rural Health. 2007 Spring;23(2):99–107. [PubMed]
4. Stoops WW, Tindall MS, Havens JR, et al. Kentucky rural stimulant use: a comparison of methamphetamine and other stimulant users. J Psychoactive Drugs. 2007 Nov;(Suppl 4):407–417. [PubMed]
5. Falck RS, Wang J, Carlson RG, Siegal HA. Crack-cocaine use and health status as defined by the SF-36. Addict Behav. 2000 Jul-Aug;25(4):579–584. [PubMed]
6. Falck RS, Wang J, Siegal HA, Carlson RG. Longitudinal application of the medical outcomes study 36-item short-form health survey with not-in-treatment crack-cocaine users. Med Care. 2000 Sep;38(9):902–910. [PubMed]
7. Falck RS, Wang J, Siegal HA, Carlson RG. Current physical health problems and their predictors among a community sample of crack-cocaine smokers in Ohio. J Psychoactive Drugs. 2003 Oct-Dec;35(4):471–478. [PubMed]
8. Borders TF, Booth BM, Falck RS, Leukefeld C, Wang J, Carlson RG. Longitudinal changes in drug use severity and physical health-related quality of life among untreated stimulant users. Addict Behav. 2009 Nov;34(11):959–964. [PMC free article] [PubMed]
9. Trivedi MH, Greer TL, Grannemann BD, et al. Stimulant reduction intervention using dosed exercise (STRIDE) - CTN 0037: study protocol for a randomized controlled trial. Trials. 2011;12:206. [PMC free article] [PubMed]
10. WHO. Composite International Diagnostic Interview, version 2.1. Geneva: World Health Organization; 1997.
11. Sangha O, Stucki G, Liang MH, Fossel AH, Katz JN. The Self-Administered Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis Rheum. 2003 Apr 15;49(2):156–163. [PubMed]
12. dela Cruz AM, Bernstein IH, Greer TL, et al. Self-rated measure of pain frequency, intensity, and burden: psychometric properties of a new instrument for the assessment of pain. J Psychiatr Res. 2014 Dec;59:155–160. [PMC free article] [PubMed]
13. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(Suppl 20):22–33. quiz 34-57. [PubMed]
14. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biological psychiatry. 2003 Sep 1;54(5):573–583. [PubMed]
15. Snaith RP, Hamilton M, Morley S, Humayan A, Hargreaves D, Trigwell P. A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale. The British journal of psychiatry : the journal of mental science. 1995 Jul;167(1):99–103. [PubMed]
16. Trivedi MH, Wisniewski SR, Morris DW, et al. Concise Health Risk Tracking scale: a brief self-report and clinician rating of suicidal risk. J Clin Psychiatry. 2011 Jun;72(6):757–764. [PubMed]
17. Fava M, Graves LM, Benazzi F, et al. A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment. The Journal of clinical psychiatry. 2006 Nov;67(11):1754–1759. [PubMed]
18. Endicott J, Nee J, Harrison W, Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull. 1993;29(2):321–326. [PubMed]
19. Ware JE, Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992 Jun;30(6):473–483. [PubMed]
20. McLellan AT, Luborsky L, Woody GE, O'Brien CP. An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index. The Journal of nervous and mental disease. 1980 Jan;168(1):26–33. [PubMed]
21. Kampman KM, Volpicelli JR, McGinnis DE, et al. Reliability and validity of the Cocaine Selective Severity Assessment. Addictive behaviors. 1998 Jul-Aug;23(4):449–461. [PubMed]
22. Sussner BD, Smelson DA, Rodrigues S, Kline A, Losonczy M, Ziedonis D. The validity and reliability of a brief measure of cocaine craving. Drug Alcohol Depend. 2006 Jul 27;83(3):233–237. [PubMed]
23. Mertens JR, Lu YW, Parthasarathy S, Moore C, Weisner CM. Medical and psychiatric conditions of alcohol and drug treatment patients in an HMO: comparison with matched controls. Arch Intern Med. 2003 Nov 10;163(20):2511–2517. [PubMed]
24. Dickey B, Normand SL, Weiss RD, Drake RE, Azeni H. Medical morbidity, mental illness, and substance use disorders. Psychiatr Serv. 2002 Jul;53(7):861–867. [PubMed]
25. Lin WC, Zhang J, Leung GY, Clark RE. Chronic physical conditions in older adults with mental illness and/ or substance use disorders. J Am Geriatr Soc. 2011 Oct;59(10):1913–1921. [PubMed]
26. Barrio G, Molist G, de la Fuente L, et al. Mortality in a cohort of young primary cocaine users: controlling the effect of the riskiest drug-use behaviors. Addict Behav. 2013 Mar;38(3):1601–1604. [PubMed]
27. Patkar AA, Batra V, Mannelli P, Evers-Casey S, Vergare MJ, Leone FT. Medical symptoms associated with tobacco smoking with and without marijuana abuse among crack cocaine-dependent patients. Am J Addict. 2005 Jan-Feb;14(1):43–53. [PubMed]